Articles tagged with Tyrosine Kinases
A new Alliance trial is exploring the effectiveness of a combination of targeted therapy and immunotherapy for patients with advanced adrenocortical carcinoma, a rare and aggressive cancer. The study aims to improve disease control and quality of life for patients with limited treatment options.
Researchers at Texas Tech University Health Sciences Center have received a $1.94 million grant to study inhibitors that target peripheral neuropathic pain. The project aims to develop novel non-opioid and non-addicting therapies capable of effectively managing chronic pain.
Researchers discuss Ibrutinib, a BTK inhibitor approved for chronic lymphocytic leukemia treatment, noting 20-25% of patients experience dose-limiting cardiovascular toxicities. A recent study identifies genetic biomarkers, such as KCNQ1 and GATA4, associated with cardiotoxic events, which may improve risk stratification.
Researchers at Kyoto University developed a new reactant demonstrating efficacy on proteins with drug-resistant mutations. The new inhibitor, ArNASA, reacts with lysine residues and is highly stable in physiological environments.
CNIO researchers have discovered a previously unknown mechanism of action for the first oncogene, c-Src. The study reveals that c-Src can autonomously activate itself through autophosphorylation, leading to cancer formation. This finding has significant implications for the development of new drugs targeting this enzyme.
A phase IIb trial found brepocitinib superior to placebo in reducing signs and symptoms of psoriatic arthritis after 16 weeks. Response rates were maintained or improved through week 52, with mostly mild or moderate side effects.
Researchers found a partial response in a patient with pancreatic acinar cell carcinoma, as well as stable disease in 11 patients, when combining riluzole with sorafenib in a phase I trial. The combination was safe and tolerable, and further exploration of its potential is warranted.
Researchers report an updated analysis from a phase I study of mivavotinib, a spleen tyrosine kinase inhibitor, in patients with relapsed/refractory B-cell lymphoma. The study showed a 45% overall response rate and median duration of response of 28.1 months in the overall cohort.
A phase 2 clinical trial has generated promising results for deucravacitinib, an oral inhibitor of tyrosine kinase 2 (TYK2), in patients with active lupus. The study found that patients treated with deucravacitinib experienced significant improvements in disease activity, with response rates ranging from 34% to 58% compared to placebo.
Researchers identified differences in PTK activity between normal and cancer kidney tissue, with Src family kinases and PI3K pathways exhibiting high activity. Ex vivo treatment of clear cell RCC with TKIs revealed that tivozanib and cabozantinib were more potent inhibitors than sunitinib or pazopanib.
CSIC scientists propose a new approach to regulate the signaling cascade of tyrosine kinases, which could lead to the development of more selective tools for research, diagnosis, or treatment of diseases. The new tool is designed to block the molecules on which kinases act, rather than inhibiting the enzymes themselves.
Elevated sFLT1 levels in mice predict preeclampsia-like symptoms, including increased angiotensin II sensitivity and decreased nitric oxide production. Treating preeclamptic mice with sildenafil reversed symptoms and improved fetal health.
Moffitt Cancer Center researchers identified 39 tyrosine kinases in sarcoma cells, which could drive tumor growth and survival. These enzymes were found to be expressed in multiple tumors, potentially limiting the effectiveness of targeted agents.
Researchers discovered a record number of tyrosine kinase genes in Monosiga brevicollis, a single-celled microbe. The microbe's signaling network is more diverse and elaborate than found in any multicellular organism.
Researchers at Rice University have engineered a modified form of the anti-cancer drug imatinib, known as WBZ_4, which targets specific cancer-causing proteins without affecting normal bodily functions. This new compound shows promise in treating gastrointestinal stromal tumors (GISTs) with reduced risk of heart toxicity.
Researchers developed a new way to study proteins in live cells, identifying interactions between Src and CrkL, and direct evidence of its role in MAP kinase pathways. This approach may lead to the development of new cancer treatments, such as targeting tyrosine kinases like Gleevec.
Researchers identified a common genetic mutation, JAK2, in patients with polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. The study used high-throughput DNA sequencing analysis to compare blood and mouth-swab samples from 164 PV patients, 115 ET patients, and 46 MMM patients.
Studies of hypereosinophilic syndrome reveal a novel mechanism for generating a cancer-causing tyrosine kinase. Gleevec treatment leads to extraordinary responses in patients, including complete recovery from severe organ damage.